- Home
- DXLG vs ATNM Comparison
DXLG vs ATNM Comparison
Compare DXLG & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- ATNM
- Stock Information
- Founded
- DXLG 1976
- ATNM 2000
- Country
- DXLG United States
- ATNM United States
- Employees
- DXLG N/A
- ATNM N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- DXLG Consumer Discretionary
- ATNM Health Care
- Exchange
- DXLG Nasdaq
- ATNM Nasdaq
- Market Cap
- DXLG 55.4M
- ATNM 50.2M
- IPO Year
- DXLG 1987
- ATNM N/A
- Fundamental
- Price
- DXLG $1.17
- ATNM $1.58
- Analyst Decision
- DXLG Strong Buy
- ATNM Strong Buy
- Analyst Count
- DXLG 1
- ATNM 2
- Target Price
- DXLG $2.50
- ATNM $4.50
- AVG Volume (30 Days)
- DXLG 73.2K
- ATNM 116.8K
- Earning Date
- DXLG 11-21-2025
- ATNM 11-13-2025
- Dividend Yield
- DXLG N/A
- ATNM N/A
- EPS Growth
- DXLG N/A
- ATNM N/A
- EPS
- DXLG N/A
- ATNM N/A
- Revenue
- DXLG $447,744,000.00
- ATNM N/A
- Revenue This Year
- DXLG N/A
- ATNM N/A
- Revenue Next Year
- DXLG $4.93
- ATNM N/A
- P/E Ratio
- DXLG N/A
- ATNM N/A
- Revenue Growth
- DXLG N/A
- ATNM N/A
- 52 Week Low
- DXLG $0.90
- ATNM $1.03
- 52 Week High
- DXLG $3.10
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- DXLG 36.16
- ATNM 42.17
- Support Level
- DXLG $1.29
- ATNM $1.56
- Resistance Level
- DXLG $1.31
- ATNM $1.64
- Average True Range (ATR)
- DXLG 0.07
- ATNM 0.06
- MACD
- DXLG -0.02
- ATNM -0.01
- Stochastic Oscillator
- DXLG 3.34
- ATNM 6.67
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.